Page 2 - Moon Shots Program News Today

Prediction model with blood test significantly improves lung cancer risk assessment compared to current guidelines

A combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia (CLL), according to researchers at The University of Texas MD Anderson Cancer Center. Findings from the single-institution Phase II study were published today in JAMA Oncology and provide the longest follow-up data on patients treated with this drug regimen.

MD Anderson researchers have discovered a new role for the metabolic enzyme, MCAD, in glioblastoma. The enzyme prevents toxic fatty acid accumulation, in addition to its normal role in energy production, and targeting MCAD led to irreversible damage and cell death specifically in cancer cells.

Antiviral T cells safe, effective as off-the-shelf therapy for painful complication after stem cell transplants A Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center found that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis (BKV-HC), a painful complication common after allogeneic stem cell transplants for patients with leukemia or lymphoma. The study was published ...

 E-Mail HOUSTON ? A Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center found that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis (BKV-HC), a painful complication common after allogeneic stem cell transplants for patients with leukemia or lymphoma. The study was published today in the Journal of Clinical Oncology. Infusion of T cells targeting BKV resulted in rap...

Date Time Genetic diversity within tumors suggests continuous evolution By analyzing tumors from more than 2,600 patients and from 38 cancer types, researchers from The University of Texas MD Anderson Cancer Center and fellow member institutions of the international Pan-Cancer Analysis of Whole Genomes Consortium have characterized the extensive genetic diversity across cancer and within individual tumors. The study, published today in Cell, found that 95% of the analyzed tumors had at least on...

In an effort to address a major challenge when analyzing large single-cell RNA-sequencing datasets, researchers from the University of Texas MD Anderson Cancer

Washington [US], January 19 (ANI): In an effort to address a major challenge when analyzing large single-cell RNA-sequencing datasets, researchers from the University of Texas MD Anderson Cancer Center have developed a new computational technique to accurately differentiate between data from cancer cells and the variety of normal cells found within tumor samples.

Credit: MD Anderson Cancer Center HOUSTON — In an effort to address a major challenge when analyzing large single-cell RNA-sequencing datasets, researchers from The University of Texas MD Anderson Cancer Center have developed a new computational technique to accurately differentiate between data from cancer cells and the variety of normal cells found within tumor samples. The work was published today in Nature Biotechnology. The new tool, dubbed CopyKAT (copy number karyotyping of aneuploid ...